Research graph
References from Immune checkpoint inhibitors plus chemotherapy for early-stage or locally –advanced triple-negative breast cancer: a systematic review and Bayesian network meta-analysis of randomized trials. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · 2024 · External reference
Triple-negative breast cancer
10.1056/nejmra1001389 · 2010 · External reference
Triple-negative breast cancer: clinical features and patterns of recurrence
10.1158/1078-0432.ccr-06-3045 · 2007 · External reference
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
10.1016/s0140-6736(13)62422-8 · 2014 · External reference
Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis
10.1158/1078-0432.ccr-19-3492 · 2020 · External reference
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
10.1186/s40425-016-0165-6 · 2016 · External reference
Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer
10.1056/nejmoa1809615 · 2018 · External reference
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
10.1016/s0140-6736(20)32531-9 · 2020 · External reference
Pembrolizumab for early triple-negative breast cancer
10.1056/nejmoa1910549 · 2020 · External reference
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
10.1016/s0140-6736(20)31953-x · 2020 · External reference
Breast cancer immunotherapy: facts and hopes
10.1158/1078-0432.ccr-16-3001 · 2018 · External reference
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
10.1093/annonc/mdz158 · 2019 · External reference
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations
10.7326/m14-2385 · 2015 · External reference
RoB 2: a revised tool for assessing risk of bias in randomised trials
10.1136/bmj.l4898 · 2019 · External reference
Camrelizumab vs placebo in combination with chemotherapy as neoadjuvant treatment in patients with early or locally advanced triple-negative breast cancer: the CamRelief randomized clinical trial
10.1001/jama.2024.23560 · 2025 · External reference
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
10.1016/j.annonc.2022.07.1940 · 2022 · External reference
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial
10.1038/s41591-025-03725-4 · 2025 · External reference
Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial
10.1001/jamaoncol.2019.6650 · 2020 · External reference
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study
10.1093/jnci/djae129 · 2024 · External reference
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013
10.1038/s41523-022-00500-3 · 2022 · External reference
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
10.1016/j.annonc.2022.02.004 · 2022 · External reference
A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial-Pembrolizumab Low dose in Addition to NACT in TNBC)
10.1016/j.annonc.2025.12.015 · 2026 · External reference
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study
10.1038/s41392-023-01700-4 · 2023 · External reference
Oncology meets immunology: the cancer-immunity cycle
10.1016/j.immuni.2013.07.012 · 2013 · External reference
PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition
10.3389/fimmu.2019.02022 · 2019 · External reference
Mechanisms of primary and secondary resistance to immune checkpoint inhibitors in cancer
10.3390/medsci7020014 · 2019 · External reference
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
10.1016/s1470-2045(17)30904-x · 2018 · External reference
Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer
10.1136/jclinpath-2016-203990 · 2017 · External reference
Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease
10.1158/2159-8290.cd-16-0577 · 2016 · External reference
CD8(+) T cell exhaustion and cancer immunotherapy
10.1016/j.canlet.2022.216043 · 2023 · External reference
Hepatectomy alters adjuvant anti-PD-1 action in a mouse model of HCC but does not compromise neoadjuvant efficacy
10.1097/hep.0000000000001731 · 2025 · External reference
Immunological aspects of cancer chemotherapy
10.1038/nri2216 · 2008 · External reference
Immunogenic cell death in cancer and infectious disease
10.1038/nri.2016.107 · 2017 · External reference
Immunogenic cell stress and death
10.1038/s41590-022-01132-2 · 2022 · External reference
Immune evasion in cancer: mechanistic basis and therapeutic strategies
10.1016/j.semcancer.2015.03.004 · 2015 · External reference
The interplay of immunotherapy and chemotherapy: harnessing potential synergies
10.1158/2326-6066.cir-15-0064 · 2015 · External reference
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
10.1038/s41591-019-0432-4 · 2019 · External reference
The hallmarks of successful anticancer immunotherapy
10.1126/scitranslmed.aat7807 · 2018 · External reference
Event-free survival with pembrolizumab in early triple-negative breast cancer
10.1056/nejmoa2112651 · 2022 · External reference
Surrogate endpoints in clinical trials: definition and operational criteria
10.1002/sim.4780080407 · 1989 · External reference
Immune-related adverse events associated with immune checkpoint blockade
10.1056/nejmra1703481 · 2018 · External reference
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline
10.1200/jop.18.00005 · 2018 · External reference
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
10.1093/annonc/mdx225 · 2017 · External reference
Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: a systematic review and meta-analysis
10.1001/jamaoncol.2024.3456 · 2024 · External reference
Different chemotherapy regimens and pathologic complete response in triple-negative breast cancer: an updated network meta-analysis of phase 3 trials
10.3390/medicina60020341 · 2024 · External reference
